ESPRIT Study in Hypogonadal Men

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

Observational study with AndroGel®, Testosterone 1% gel therapy (ESPRIT) in hypogonadal men in the community over 6 months.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Collaborator: Fovea
• Treatments: Methyltestosterone; Testosterone; Testosterone 17 beta-cypionate; Testosterone enanthate; Testosterone undecanoate

Criteria

Inclusion Criteria

1. Male patients >= 18 years of age

2. Hypogonadism not previously treated with testosterone

3. Testosterone deficiency confirmed clinically and biochemically

4. Being prescribed AndroGel® 1% in accordance with the local summary of product characteristics

Exclusion Criteria

1. According to the contra-indications,

2. Unwilling or unable to sign informed consent form